chronic thromboembolic pulmonary hypertension
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: PH patients diagnosed with pulmonary hypertension older than 18 years can be included in this study. Cells will be only isolated from chronic thromboembolic pulmonary hypertension (CTEPH) patients undergoing a pulmonary endarterectomy. Blood will be drawn from CTEPH as wel as pulmonary arterial hypertension patients and healthy controls
Exclusion criteria
Exclusion criteria: PH patients who are categorized in group 2, 3 and 5 of the WHO classes pulmonary hypertension (PH), are excluded from this study. Blood from control subjects are only considered as controls if they do not have PH and/or do not do have any bleeding disorders or take any medication that acts on the coagulation cascade.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main objective of this study is to investigate the role of the CTEPH endothelium in platelet adhesion and clot formation. Pulmonary arterial endothelial cells (ECs) will be characterized before and after interaction with peripheral blood under shear stress. Cellular phenotypes of PAECs from CTEPH patients are compared to PAECs from control subjects, and possible underlying mechanisms will be investigated based on gained results. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Characterize PAECs coagulation factors expression profile. We will compare control and CTEPH-PAECs to identify differences. 2. Study endothelial-blood interaction under high levels of fluid shear stress to investigate how the diseased endothelium influences coagulation under conditions resembling human hemodynamics. We will compare control, CTEPH and PAH-PAECs to identify differences. 3. Characterize plasma from PH patients on soluble protein markers that influences cellular behavior to express pro-thromboembolic proteins. We will compare plasma from control, CTEPH and PAH-PAECs to identify differences. 4. Confirm if increased thrombosis found in CTEPH is a vascular problem rather than a hemostatic problem. We will do this by studying endothelial-blood interaction where control, CTEPH and PAH blood will be perfused over control PAECs to compare and identify differences. 5. Investigate potential drug treatments that could act on the coagulation pathway to prevent recurrent or to treat CTEPH. | — |
Countries
Netherlands
Outcome results
None listed